Liposomal Bupivacaine vs Standard Penile Block for Hypospadias Repair
NCT ID: NCT04479371
Last Updated: 2021-08-16
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
PHASE1
Study Classification
INTERVENTIONAL
Study Start Date
2021-07-31
Study Completion Date
2023-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigator proposes a prospective randomized study of males with hypospadias to either bupivacaine penile block or liposomal bupivacaine block for hypospadias repair, Figure 3. The investigator will use an envelope system for randomizing 1:1 to either group.
Approach to surgery will be determined by the location of the urethral meatus and degree of chordee along with the amount of skin available and provider preference. Patients who have an ASA classification of 3 or greater, renal or hepatic dysfunction, less than 6 months of age, or refuse the risk of using liposomal bupivacaine during the procedure will be excluded.
The goal is to compare the pain scores of standard bupivacaine penile blocks versus liposomal bupivacaine penile blocks for patients undergoing hypospadias surgery. This is also an opportunity to use liposomal bupivacaine in children as a regional local block for penile surgery. Patients will be enrolled at Children's Medical Center from July 1st, 2019 until 100 total patients are accrued, as specified in our sample size calculation. It is estimated that the trial will be completed in five years with hopes of potentially reaching 100 patients within two years.
Approach to surgery will be determined by the location of the urethral meatus and degree of chordee along with the amount of skin available and provider preference. Patients who have an ASA classification of 3 or greater, renal or hepatic dysfunction, less than 6 months of age, or refuse the risk of using liposomal bupivacaine during the procedure will be excluded.
The goal is to compare the pain scores of standard bupivacaine penile blocks versus liposomal bupivacaine penile blocks for patients undergoing hypospadias surgery. This is also an opportunity to use liposomal bupivacaine in children as a regional local block for penile surgery. Patients will be enrolled at Children's Medical Center from July 1st, 2019 until 100 total patients are accrued, as specified in our sample size calculation. It is estimated that the trial will be completed in five years with hopes of potentially reaching 100 patients within two years.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Liposomal Bupivacaine vs. Bupivacaine Hydrochloride and Lidocaine During Suburethral Sling Placement
NCT02875015
Postoperative Pain
COMPLETED
NA
Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine
NCT03802864
Male Infertility
COMPLETED
PHASE4
Liposomal Bupivacaine To Control Post-Operative Pain Following BMG
NCT03720223
Urethral Stricture
COMPLETED
PHASE3
Extended Delivery of Bupivacaine Study in Herniorrhaphy
NCT04102267
Analgesia
COMPLETED
PHASE4
Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel
NCT04826484
Urologic Diseases
Hypospadias
Undescended Testes
+3 more
TERMINATED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Male patients who are greater than 6 months of age will be enrolled in the study prior to elective outpatient hypospadias repair with ASA class 1-2. For a male who meets the inclusion criteria, after informed consent is obtained, he will be randomized at a 1:1 basis to standard penile block with bupivacaine or penile block with liposomal bupivacaine. All patients will be pre-medicated per standard practice with 0.1-0.2 mg PO hydrocodone and 0.25-0.35 mg PO versed.
* Control patients will receive a standardized amount of 0.25% bupivacaine based on age-based ideal body weight calculated as follows: 6 months to 1 year old, 2.5 mg/kg; \>1-year-old, 3 mg/kg. Calculating volume of agent that can be administered in mL = allowable ideal body weight dose (mg/kg) x (weight in kg) x (1/ concentration of local anesthetic agent). For example, the average 9-month old male is around 9 kg, therefore, they will receive 9 mL of 0.25% bupivacaine (2.5 mg/mL).
* Treatment patients will receive Liposomal Bupivacaine (Exparel) 1.3% (266mg/20mL or 133mg/10mL) based on current PK studies for the agent. A dose of 4mg/kg will be used. For example, using the fact that the average 9-month old is around 9kg the patient would receive 2.7 mL of liposomal bupivacaine. Since the liposomal bupivacaine has a delayed onset of action, the patients in this arm would receive 0.25% bupivacaine for the immediate analgesic needed for the operative procedure. According to the prescribing information for Pacira pharmaceuticals, bupivacaine HCl can be administered immediately before or in the same syringe as liposomal bupivacaine (Exparel). This is only true as long as the ratio of bupivacaine HCl to Liposomal bupivacaine (Experal) dose does not exceed 1:2 ratio of the agents. Also, a 10mL vial of liposomal bupivacaine (Experal) contains 133mg of free base bupivacaine, which is the molar equivalent of 150mg of bupivacaine HCl. (reference Pacira prescribing information) Therefore, if the dose of 2.7ml of liposomal bupivacaine is used for a 9kg child, then the patient is allowed up to 18mg of bupivacaine HCl to be mixed with the liposomal bupivacaine (1:2 ration or 50% rule from Pacira prescribing information). Our patients will receive a 0.25% bupivacaine dosage that will be calculated using the ideal body weight calculation as stated above, but instead of using 2.5mg/kg dosage it would need to be 2mg/kg so the 50% ratio is met to fit the pharmacodynamics of using liposomal bupivacaine in a safe and predictable manner. Therefore, for the 9kg patient, he would receive 2.7 mL of liposomal bupivacaine and 7.2 mL of 0.25% bupivacaine for a total volume of 9.9 mL of total volume.
* Using the 0.25% bupivacaine in the control arm and experimental arm allows the volume of the local anesthetic to be close in-between the cohorts and ideal for giving a complete penile ring block, since the volume of liposomal bupivacaine needed is very small. The use of 0.25% bupivacaine is important in the liposomal bupivacaine arm, because the liposomal bupivacaine has a delayed release and could not offer local anesthesia until closer to 45 minutes after application. This could potentially lead to patients requiring more systemic anesthesia if liposomal bupivacaine is used alone. Therefore, like many other pediatric providers using liposomal bupivacaine, it will be given in conjunction with 0.25% bupivacaine to improve immediate local anesthesia.
* To standardize the technique of the blocks, each block will be given in the same fashion by each of the pediatric urology providers.
1\. Enrollment and Consenting:
* Patients that fit the inclusion criteria will have the trial discussed with them in the preoperative consultation room with the attending urologist. If the patients' consent to being enrolled, they will receive a copy of the Face, Legs, Activities, Cry, Consolability (FLACC) scale, the post procedure log sheet for the study to record the FLACC scores and PRN medication doses and indication for PRN medication administration, and they will also be shown a video on how to use the FLACC scoring system.
* One of the concerns for using the FLACC as an outcome measure of postoperative pain and a measure of how effective liposomal bupivacaine is in comparison to bupivacaine alone, is the intra-operator differences among patients' parents and reporting a score. We are attempting to control for this by showing a video with an example patient and scoring of this patient for each family to view. This video will be available to enrolled families via email so they can show it to other family members or caregivers (potentially grandparents or nanny/babysitters) who may be scoring the child in the post-operative period, but were not present on the day of surgery, or during the preoperative consultation.
Day of Surgery
* The parent/LAR will most likely be approached for consenting at the preoperative consultation, but will be given ample time to consider, and we will verify they continue to desire to participate on the day of their surgery by the research fellow.
* After the patient is enrolled, the research fellow will pull the next envelope to determine which group each patient will be assigned to.
* The anesthesia team will receive the treatment arm assignment 0.25% bupivacaine HCl alone vs. 0.25% bupivacaine and 1.3% liposomal bupivacaine from the research team member. And enter the order for local anesthetic agent in Epic that will be used during the surgery for the penile block with the appropriate patient weight.
* The agent will be processed by pharmacy and dispensed to the OR for the urologist to administer as a penile ring block at the induction of anesthesia. The urologist and anesthesiologist will be aware of the agent given to the patient for safety concerns, but this should not interfere with trial endpoints since scores will be awarded by the parents who are blinded to the anesthetic agent used.
* The block will be administered in a standard fashion (ring block) by the pediatric urologist in either arm of the study.
2\. PACU
* In the PACU, patients will have their pain assessed by the non-verbal FLACC pain scale, Figure 4.
* Pain scores will be recorded at 5, 30, 60, and 90 minutes' post-procedure as well as at the time of discharge from the PACU to home. These scores will be given by the PACU nursing staff and separately by the parents for consistency in scoring the post-operative period of the patient.
* The nursing staff will be given an in-service education about the trial and using the FLACC scoring scale. They will also be given the opportunity to score patients alongside a provider during the initial pilot of the study with either the pediatric urologist, pediatric urology fellow, or pediatric anesthesiologist. We will also be collaborating with a member of the PACU staff to serve as part of the research personnel (potentially a nurse who has an academic interest or seeking an opportunity to further their education in research) to further offer consistency of PACU nursing staff education and transition of information to the patients' parents. This will hopefully decrease the concern for inconsistency of parent education and nursing PACU scoring of patient's pain.
* In addition, the amount of narcotic pain medication required (if any) will be documented. Any requirement for narcotic pain medication in PACU will be considered a failure of the block and these patients will be assigned a pain score of zero out of 10 on the FLACC scale.
* We will also monitor patients for emergence delirium and if the patient required a bolus of propofol or dexmedetomidine in the PACU. This will be reported in the medical record and factored in when interoperating results.
* The patient will be discharged from PACU with a prescription for the weight-based dosage of acetaminophen and ibuprofen. This will allow the medications to be given at the appropriate weight dosage and for the patients to potentially have the agents covered by the insurance or bought over the counter.
* Patients will also be given a prescription for oxybutynin to use for bladder spasm (catheter associated pain) that will be weight based to use on a PRN basis.
3\. Post-Operative Scoring using the FLACC non-verbal pain scale
* The parents will be asked to assess their child's pain using the FLACC scale in 6 hour intervals (while awake and if sleeping will be assigned a 0 for that time period). If the child has a score of \>4 the patient will be given a weight calculated dose of acetaminophen or ibuprofen alternating each time a score \> 4 occurs. If the patient is experiencing a score \>7 then patient will be administered a weight based dosage of oral narcotic medication. \[20\]
* All patients will be sent home with PRN oral acetaminophen and Ibuprofen pain medication per our department's standard practice. PACU RNs will be blinded to the block that each patient will receive. The anesthesiologist and urologist will be the only people who are aware of the randomization for patient safety concerns, but will never be assigning a patient FLACC score therefore this should not impact results.
* The caregiver of the child will be given a copy of the FLACC and asked to record their child's score in 6 hour intervals and any PRN pain medications administered and the score at the time of medication administration.
* The highest score given in the first 24, 48, 72 hours will be used as the values for analysis for Time 1, 2, and 3 respectively. We will also look at the total sum of pain scores per 24-hour period. (If the parents give more than 1 score in a 6-hour window then the highest score from that period will be used in the calculation).
* During the randomization process, there will be random patients (most likely every 4th patient for a total of 25 patients throughout the course of the trial) selected for an additional post-operative phone call at 24 hours. This phone call will be done by a member of the research team via FaceTime or Skype, where the ability to visualize the patient and award a FLACC score alongside the parent/caregiver can be conducted. This will hopefully be able to support the concept of parents being educated in the scoring system in hopes of eliminating intraoperative scoring error between families when compared to the research team member.
* Each family will receive a standard phone call at 72 hours to verify any adverse events, presentations to ER or another provider prior to scheduled follow up appointment, requirements for pain medication, and to collect the parentally recorded pain scale data at their follow up appointment which occurs at 1 week (5-10 days postoperatively) when the patient presents for catheter removal. At that time, the parents will be interviewed and asked about the postoperative course and any complications such as UTI, fever, or adverse events as defined above.
* The parents will be given a survey after the initial post-operative course to inquire about their experience and their opinion on their child's post-operative pain.
* Control patients will receive a standardized amount of 0.25% bupivacaine based on age-based ideal body weight calculated as follows: 6 months to 1 year old, 2.5 mg/kg; \>1-year-old, 3 mg/kg. Calculating volume of agent that can be administered in mL = allowable ideal body weight dose (mg/kg) x (weight in kg) x (1/ concentration of local anesthetic agent). For example, the average 9-month old male is around 9 kg, therefore, they will receive 9 mL of 0.25% bupivacaine (2.5 mg/mL).
* Treatment patients will receive Liposomal Bupivacaine (Exparel) 1.3% (266mg/20mL or 133mg/10mL) based on current PK studies for the agent. A dose of 4mg/kg will be used. For example, using the fact that the average 9-month old is around 9kg the patient would receive 2.7 mL of liposomal bupivacaine. Since the liposomal bupivacaine has a delayed onset of action, the patients in this arm would receive 0.25% bupivacaine for the immediate analgesic needed for the operative procedure. According to the prescribing information for Pacira pharmaceuticals, bupivacaine HCl can be administered immediately before or in the same syringe as liposomal bupivacaine (Exparel). This is only true as long as the ratio of bupivacaine HCl to Liposomal bupivacaine (Experal) dose does not exceed 1:2 ratio of the agents. Also, a 10mL vial of liposomal bupivacaine (Experal) contains 133mg of free base bupivacaine, which is the molar equivalent of 150mg of bupivacaine HCl. (reference Pacira prescribing information) Therefore, if the dose of 2.7ml of liposomal bupivacaine is used for a 9kg child, then the patient is allowed up to 18mg of bupivacaine HCl to be mixed with the liposomal bupivacaine (1:2 ration or 50% rule from Pacira prescribing information). Our patients will receive a 0.25% bupivacaine dosage that will be calculated using the ideal body weight calculation as stated above, but instead of using 2.5mg/kg dosage it would need to be 2mg/kg so the 50% ratio is met to fit the pharmacodynamics of using liposomal bupivacaine in a safe and predictable manner. Therefore, for the 9kg patient, he would receive 2.7 mL of liposomal bupivacaine and 7.2 mL of 0.25% bupivacaine for a total volume of 9.9 mL of total volume.
* Using the 0.25% bupivacaine in the control arm and experimental arm allows the volume of the local anesthetic to be close in-between the cohorts and ideal for giving a complete penile ring block, since the volume of liposomal bupivacaine needed is very small. The use of 0.25% bupivacaine is important in the liposomal bupivacaine arm, because the liposomal bupivacaine has a delayed release and could not offer local anesthesia until closer to 45 minutes after application. This could potentially lead to patients requiring more systemic anesthesia if liposomal bupivacaine is used alone. Therefore, like many other pediatric providers using liposomal bupivacaine, it will be given in conjunction with 0.25% bupivacaine to improve immediate local anesthesia.
* To standardize the technique of the blocks, each block will be given in the same fashion by each of the pediatric urology providers.
1\. Enrollment and Consenting:
* Patients that fit the inclusion criteria will have the trial discussed with them in the preoperative consultation room with the attending urologist. If the patients' consent to being enrolled, they will receive a copy of the Face, Legs, Activities, Cry, Consolability (FLACC) scale, the post procedure log sheet for the study to record the FLACC scores and PRN medication doses and indication for PRN medication administration, and they will also be shown a video on how to use the FLACC scoring system.
* One of the concerns for using the FLACC as an outcome measure of postoperative pain and a measure of how effective liposomal bupivacaine is in comparison to bupivacaine alone, is the intra-operator differences among patients' parents and reporting a score. We are attempting to control for this by showing a video with an example patient and scoring of this patient for each family to view. This video will be available to enrolled families via email so they can show it to other family members or caregivers (potentially grandparents or nanny/babysitters) who may be scoring the child in the post-operative period, but were not present on the day of surgery, or during the preoperative consultation.
Day of Surgery
* The parent/LAR will most likely be approached for consenting at the preoperative consultation, but will be given ample time to consider, and we will verify they continue to desire to participate on the day of their surgery by the research fellow.
* After the patient is enrolled, the research fellow will pull the next envelope to determine which group each patient will be assigned to.
* The anesthesia team will receive the treatment arm assignment 0.25% bupivacaine HCl alone vs. 0.25% bupivacaine and 1.3% liposomal bupivacaine from the research team member. And enter the order for local anesthetic agent in Epic that will be used during the surgery for the penile block with the appropriate patient weight.
* The agent will be processed by pharmacy and dispensed to the OR for the urologist to administer as a penile ring block at the induction of anesthesia. The urologist and anesthesiologist will be aware of the agent given to the patient for safety concerns, but this should not interfere with trial endpoints since scores will be awarded by the parents who are blinded to the anesthetic agent used.
* The block will be administered in a standard fashion (ring block) by the pediatric urologist in either arm of the study.
2\. PACU
* In the PACU, patients will have their pain assessed by the non-verbal FLACC pain scale, Figure 4.
* Pain scores will be recorded at 5, 30, 60, and 90 minutes' post-procedure as well as at the time of discharge from the PACU to home. These scores will be given by the PACU nursing staff and separately by the parents for consistency in scoring the post-operative period of the patient.
* The nursing staff will be given an in-service education about the trial and using the FLACC scoring scale. They will also be given the opportunity to score patients alongside a provider during the initial pilot of the study with either the pediatric urologist, pediatric urology fellow, or pediatric anesthesiologist. We will also be collaborating with a member of the PACU staff to serve as part of the research personnel (potentially a nurse who has an academic interest or seeking an opportunity to further their education in research) to further offer consistency of PACU nursing staff education and transition of information to the patients' parents. This will hopefully decrease the concern for inconsistency of parent education and nursing PACU scoring of patient's pain.
* In addition, the amount of narcotic pain medication required (if any) will be documented. Any requirement for narcotic pain medication in PACU will be considered a failure of the block and these patients will be assigned a pain score of zero out of 10 on the FLACC scale.
* We will also monitor patients for emergence delirium and if the patient required a bolus of propofol or dexmedetomidine in the PACU. This will be reported in the medical record and factored in when interoperating results.
* The patient will be discharged from PACU with a prescription for the weight-based dosage of acetaminophen and ibuprofen. This will allow the medications to be given at the appropriate weight dosage and for the patients to potentially have the agents covered by the insurance or bought over the counter.
* Patients will also be given a prescription for oxybutynin to use for bladder spasm (catheter associated pain) that will be weight based to use on a PRN basis.
3\. Post-Operative Scoring using the FLACC non-verbal pain scale
* The parents will be asked to assess their child's pain using the FLACC scale in 6 hour intervals (while awake and if sleeping will be assigned a 0 for that time period). If the child has a score of \>4 the patient will be given a weight calculated dose of acetaminophen or ibuprofen alternating each time a score \> 4 occurs. If the patient is experiencing a score \>7 then patient will be administered a weight based dosage of oral narcotic medication. \[20\]
* All patients will be sent home with PRN oral acetaminophen and Ibuprofen pain medication per our department's standard practice. PACU RNs will be blinded to the block that each patient will receive. The anesthesiologist and urologist will be the only people who are aware of the randomization for patient safety concerns, but will never be assigning a patient FLACC score therefore this should not impact results.
* The caregiver of the child will be given a copy of the FLACC and asked to record their child's score in 6 hour intervals and any PRN pain medications administered and the score at the time of medication administration.
* The highest score given in the first 24, 48, 72 hours will be used as the values for analysis for Time 1, 2, and 3 respectively. We will also look at the total sum of pain scores per 24-hour period. (If the parents give more than 1 score in a 6-hour window then the highest score from that period will be used in the calculation).
* During the randomization process, there will be random patients (most likely every 4th patient for a total of 25 patients throughout the course of the trial) selected for an additional post-operative phone call at 24 hours. This phone call will be done by a member of the research team via FaceTime or Skype, where the ability to visualize the patient and award a FLACC score alongside the parent/caregiver can be conducted. This will hopefully be able to support the concept of parents being educated in the scoring system in hopes of eliminating intraoperative scoring error between families when compared to the research team member.
* Each family will receive a standard phone call at 72 hours to verify any adverse events, presentations to ER or another provider prior to scheduled follow up appointment, requirements for pain medication, and to collect the parentally recorded pain scale data at their follow up appointment which occurs at 1 week (5-10 days postoperatively) when the patient presents for catheter removal. At that time, the parents will be interviewed and asked about the postoperative course and any complications such as UTI, fever, or adverse events as defined above.
* The parents will be given a survey after the initial post-operative course to inquire about their experience and their opinion on their child's post-operative pain.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hypospadias
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Two arms with one receiving liposomal bupivacaine in their penile block vs one receiving standard bupivacaine
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Participants
Participants will be blinded as to which block they received
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liposomal bupivacaine
a penile block administered with novel liposomal bupivacaine during hypospadias repair
Group Type
EXPERIMENTAL
Liposomal bupivacaine
Intervention Type
DRUG
Injecting liposomal bupivacaine for a penile block for analgesia for hypospadias repair
Standard Penile Block
Standard weight based bupivacaine penile block during hypospadias repair
Group Type
ACTIVE_COMPARATOR
Bupivacaine
Intervention Type
DRUG
Standard bupivacaine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liposomal bupivacaine
Injecting liposomal bupivacaine for a penile block for analgesia for hypospadias repair
Intervention Type
DRUG
Bupivacaine
Standard bupivacaine
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
exparel
0.25% Bupivacaine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males aged 6 months to 24 months of all races and ethnicities that have hypospadias requiring surgical intervention and post-operative urethral catheterization.
Exclusion Criteria
* Males who are not age 6 mo. to 24 months, those who do not have a diagnosis of hypospadias, those who have an ASA class of 3 or greater or known liver or renal impairment, or who have an allergy to local anesthetics such as lidocaine, bupivacaine, etc.
Minimum Eligible Age
6 Months
Maximum Eligible Age
24 Months
Eligible Sex
MALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas Southwestern Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Craig Peters
Chief of Pediatric Urology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Craig Peters, MD
Role: PRINCIPAL_INVESTIGATOR
UT Southwestern
References
Explore related publications, articles, or registry entries linked to this study.
Dadure, C., et al., Regional Anesthesia in Children in Miller's Anesthesia, R.E. Miller, Lars. Fleisher,Lee. Wiener-Kronish,Jeanine. Cohen,Neal. Young,William., Editor. 2015, Elsevier: Philadelphia, PA. p. 2706-2756
Reference Type
BACKGROUND
Tutuncu AC, Kendigelen P, Ashyyeralyeva G, Altintas F, Emre S, Ozcan R, Kaya G. Pudendal Nerve Block Versus Penile Nerve Block in Children Undergoing Circumcision. Urol J. 2018 May 3;15(3):109-115. doi: 10.22037/uj.v0i0.4292.
Reference Type
BACKGROUND
Naja Z, Al-Tannir MA, Faysal W, Daoud N, Ziade F, El-Rajab M. A comparison of pudendal block vs dorsal penile nerve block for circumcision in children: a randomised controlled trial. Anaesthesia. 2011 Sep;66(9):802-7. doi: 10.1111/j.1365-2044.2011.06753.x. Epub 2011 Jul 25.
Reference Type
BACKGROUND
Gray, H., Anatomy of the human body. 20 ed. 1918, Philidelphia: Lea & Febiger. 968
Reference Type
BACKGROUND
Richard BM, Ott LR, Haan D, Brubaker AN, Cole PI, Nelson KG, Ross PE, Rebelatto MC, Newton PE. The safety and tolerability evaluation of DepoFoam bupivacaine (bupivacaine extended-release liposome injection) administered by incision wound infiltration in rabbits and dogs. Expert Opin Investig Drugs. 2011 Oct;20(10):1327-41. doi: 10.1517/13543784.2011.611499. Epub 2011 Aug 26.
Reference Type
BACKGROUND
Chahar P, Cummings KC 3rd. Liposomal bupivacaine: a review of a new bupivacaine formulation. J Pain Res. 2012;5:257-64. doi: 10.2147/JPR.S27894. Epub 2012 Aug 14.
Reference Type
BACKGROUND
Mantripragada S. A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res. 2002 Sep;41(5):392-406. doi: 10.1016/s0163-7827(02)00004-8.
Reference Type
BACKGROUND
Mowat JJ, Mok MJ, MacLeod BA, Madden TD. Liposomal bupivacaine. Extended duration nerve blockade using large unilamellar vesicles that exhibit a proton gradient. Anesthesiology. 1996 Sep;85(3):635-43. doi: 10.1097/00000542-199609000-00024.
Reference Type
BACKGROUND
Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm. 1989 Aug;46(8):1576-87.
Reference Type
BACKGROUND
Dullenkopf A, Borgeat A. [Local anesthetics. Differences and similarities in the "-cains"]. Anaesthesist. 2003 Apr;52(4):329-40. doi: 10.1007/s00101-003-0463-5. German.
Reference Type
BACKGROUND
Pacira Pharmaceuticals. Exparel: Bupivacaine Liposome Injectable Suspension. [Prescribing Information]. Parsippany, NJ [Accessed August 23, 2018]. Available from: https://www.exparel.com/hcp/prescriptioninformation.pdf.
Reference Type
BACKGROUND
Wolfe JW, Butterworth JF. Local anesthetic systemic toxicity: update on mechanisms and treatment. Curr Opin Anaesthesiol. 2011 Oct;24(5):561-6. doi: 10.1097/ACO.0b013e32834a9394.
Reference Type
BACKGROUND
Bergese SD, Onel E, Morren M, Morganroth J. Bupivacaine extended-release liposome injection exhibits a favorable cardiac safety profile. Reg Anesth Pain Med. 2012 Mar-Apr;37(2):145-51. doi: 10.1097/AAP.0b013e31823d0a80.
Reference Type
BACKGROUND
Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011 Sep;28(9):776-88. doi: 10.1007/s12325-011-0052-y. Epub 2011 Aug 12.
Reference Type
BACKGROUND
Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. 2012 Oct;19(5):530-6. doi: 10.1016/j.knee.2011.12.004. Epub 2012 Jan 28.
Reference Type
BACKGROUND
Davidson EM, Barenholz Y, Cohen R, Haroutiunian S, Kagan L, Ginosar Y. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth Analg. 2010 Apr 1;110(4):1018-23. doi: 10.1213/ANE.0b013e3181d26d2a.
Reference Type
BACKGROUND
Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011 Dec;54(12):1552-9. doi: 10.1097/DCR.0b013e318232d4c1.
Reference Type
BACKGROUND
Smoot JD, Bergese SD, Onel E, Williams HT, Hedden W. The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: a randomized, double-blind, active-control study. Aesthet Surg J. 2012 Jan;32(1):69-76. doi: 10.1177/1090820X11430831. Epub 2011 Dec 16.
Reference Type
BACKGROUND
Day KM, Nair NM, Sargent LA. Extended Release Liposomal Bupivacaine Injection (Exparel) for Early Postoperative Pain Control Following Palatoplasty. J Craniofac Surg. 2018 Jul;29(5):e525-e528. doi: 10.1097/SCS.0000000000004591.
Reference Type
BACKGROUND
Manworren RC, Hynan LS. Clinical validation of FLACC: preverbal patient pain scale. Pediatr Nurs. 2003 Mar-Apr;29(2):140-6.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STU-2020-0686
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
NCT06411795
RECRUITING
PHASE2
A Comparison of the Efficacy of Sacral Erector Spinae Plane Block and Penile Block in Circumcision Surgery
NCT07097844
NOT_YET_RECRUITING
PHASE4
Pudendal Block Using Liposomal Bupivacaine vs. Standard Treatment During Sacrospinous Ligament Fixation
NCT03664986
UNKNOWN
PHASE4
Postoperative Pain Relief in Children: Comparing Caudal Bupivacaine Alone Versus Bupivacaine With Dexmedetomidine for Infra-Umbilical Surgeries Under General Anesthesia
NCT07121764
COMPLETED
PHASE4
Liposomal Bupivacaine in Adductor Canal Blocks (ACB)
NCT04539730
WITHDRAWN
PHASE4
Effect of Intravenous Dexamethasone With Pudendal Nerve Block on Postoperative Pain in Pediatric Hypospadias Repair
NCT03902249
COMPLETED
PHASE4
Erector Spinae Block for Spine Surgery
NCT05417113
TERMINATED
PHASE4
Liposomal Bupivacaine Versus Bupivacaine Plain for Operative Pain Management of Forefoot Surgery
NCT04751344
UNKNOWN
PHASE4
Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty
NCT03182933
TERMINATED
PHASE4
Posterior Quadratus Lumborum Block Using 0.125% Versus 0.25% Bupivacaine for Analgesia in Children Undergoing LPEC
NCT04998071
UNKNOWN
NA
Randomized Trial of Ropivacaine & Bupivacaine for Inflatable Penile Prosthesis
NCT04801368
COMPLETED
PHASE4
Effect of Adding Different Concentrations of Dexmedetomidine to Bupivacaine in Caudal Block for Pediatrics
NCT06668220
NOT_YET_RECRUITING
PHASE1
Post-operative Pain Control-TAP Block Using Exparel vs. Marcaine for Hernia Repairs
NCT05177991
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Erector Spinae Plane Block with Dexmedetomidine and Bupivacain Versus Dexamethasone and Bupivacain for Postoperative Analgesia in Patients Undergoing Abdominal Surgeries
NCT06658418
NOT_YET_RECRUITING
PHASE1
Dexmedetomidine Combined With Bupivacaine for Erector Spinae Plane Block
NCT05590234
COMPLETED
PHASE1/PHASE2
PAIN - Postoperative Analgesia INvestigation
NCT02111746
COMPLETED
PHASE4
Percutaneous Rectus Sheath Block Versus Intra-operative Rectus Sheath Block for Pediatric Umbilical Hernia Repair
NCT02341144
COMPLETED
NA
Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty
NCT02341079
WITHDRAWN
PHASE2/PHASE3
Liposomal Bupivacaine and Bupivacaine for TTMPB in Median Sternotomy
NCT06646172
RECRUITING
NA
Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters
NCT05972018
RECRUITING
PHASE4
The Analgesic Efficacy of Two Bupivacaine Concentrations for Combined Ilioinguinal and Iliohypogastric Nerve Block in Postherniorrhaphy Pain
NCT05687981
UNKNOWN
EARLY_PHASE1
Efficacy of Liposomal Bupivacaine for Prolonged Postoperative Analgesia in Patient Undergoing Breast Reconstruction With Tissue Expander
NCT04278846
COMPLETED
PHASE4
Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling
NCT02591888
TERMINATED
PHASE4
Addition of Neostigmine to Levobupivacaine
NCT04492319
COMPLETED
NA
Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion
NCT03745040
SUSPENDED
PHASE4